Survival of patients with head and neck cancer: Impact of physical status and comorbidities

Strahlentherapie und Onkologie

Volumn 188, Issue 1, 2012, Pages 62-70

  Sadat, F ^a   Wienke, A ^b   Dunst, J ^c   Kuhnt, T ^d  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Chemotherapy; Comorbidity; Head and neck neoplasms; Karnofsky Performance Index; Radiotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN C; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMORBIDITY; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEALTH STATUS; HUMAN; KARNOFSKY PERFORMANCE INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; RADIATION DOSE FRACTIONATION; THREE DIMENSIONAL IMAGING;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; COMORBIDITY; DOSE FRACTIONATION; FEMALE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIATION INJURIES; RISK FACTORS;

EID: 84856344236     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-011-0009-8     Document Type: Article

References (31)

1. Bradley JD, Ieumwananonthachai N, Purdy JA et al (2002) Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52:49-57 (Pubitemid 34041565)
2. Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23:1125-1135 (Pubitemid 46202268)
3. Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies. J Chronc Dis 40:373-383 (Pubitemid 17055592)
4. Cleary PD, Greenfield SG, Mulley AG et al (1991) Variation in length of stay and outcomes for six medical and surgical conditions in Massachusetts and California. JAMA 266:73-79
5. Dietl B, Marienhagen J, Schaefer C et al (2007) Survival with distant metastatic disease in head and neck cancer. A retrospective analysis. HNO 55:788-791
6. Dunst J, Stadler P, Becker A et al (2003) Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 179:521-526 (Pubitemid 36966408)
7. Fietkau R (2000) Tumor volume as a prognostic factor in the radiotherapy of carcinomas in the head-neck area. Strahlenther Onkol 176:382-383
8. Gunn GB, Endres EJ, Parker B et al (2010) A phase I/II study of altered fractionated IMRT alone for intermediate T-stage oropharyngeal carcinoma. Strahlenther Onkol 186:489-495
9. Hall SF, Rochon PA, Streiner DL et al (2002) Measuring comorbidity in patients with head and neck cancer. Laryngoscope 112:1988-1996 (Pubitemid 35283461)
10. Jeremic B, Milicic B (2009) Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol 32:63-68
11. Kaplan MH, Feinstein AR (1974) The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronc Dis 27:387-404
12. Karnofsky DA, Abelmann WH, Craver LF et al (1948) The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1:634-656
13. Kuhnt T, Janich M, Götz U et al (2006) Presentation of a 3D conformal radiotherapy technique for head-and-neck tumors resulting in substantial protection of the parotid glands. Strahlenther Onkol 182:325-330 (Pubitemid 43727350)
14. Kuhnt T, Klockenbrink U, Knipping S et al (2011) Adjuvant low single dose cisplatin-based concurrent radiochemotherapy of oral cavity and oropharynx carcinoma: impact of extracapsular nodal spread on distant metastases. Strahlenther Onkol 187:292-299
15. Kuhnt T, Mueller AC, Pelz T et al (2005) Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy. J Cancer Res Clin Oncol 131:758-764 (Pubitemid 41577953)
16. Kreppel M, Drebber U, Eich HT et al (2011) Combined-modality treatment in advanced oral squamous cell carcinoma: primary surgery followed by adjuvant concomitant radiochemotherapy. Strahlenther Onkol 187:555-560
17. Linn BS, Linn MW, Lee G (1968) Cumulative illness rating scale. J Am Geriatr Soc 5:622-626
18. Paleri V, Wight RG, Silver CE et al (2010) Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol 46:712-719
19. Rades D, Stoehr M, Meyners T et al (2008) Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer. Strahlenther Onkol 184:198-205 (Pubitemid 351508132)
20. Ragin CC, Modugno F, Gollin SM et al (2007) The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86:104-114
21. Robert Koch Institut (ed) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland (2010) Krebs in Deutschland 2005/2006. Häufigkeiten und Trends, 7. edition. Berlin
22. Rubin P, Constine LS, Fajardo LF et al (1995) RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 31:1041-1042
23. Sanabria A, Carvalho AL, Vartanian JG et al (2007) Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 14:1449-1457 (Pubitemid 46536825)
24. Schafer U, Micke O, Mueller SB et al (2003) Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 179:527-534 (Pubitemid 36966409)
25. Steinmann D, Cerny B, Karstens JH et al (2009) Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis. Strahlenther Onkol 185:682-688
26. Studer G, Seifert B, Glanzmann C (2008) Prediction of distant metastasis in head neck cancer patients: implications for induction chemotherapy and pre-treatment staging? Strahlenther Onkol 184:580-585
27. Tribius S, Kronemann S, Kilic Y et al (2009) Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck. Strahlenther Onkol 185:675-681
28. VonKorff M, Wagner EH, Saunders K (1992) A chronic disease score from automated pharmacy data. J Clin Epidemiol 45:197-203
29. Wolff HA, Bosch J, Jung K, Overbeck T et al (2010) High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol 186:262-268
30. Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky Performance Status. Cancer 45:222-224
31. Zubrod CG, Schneiderman M, Frei E et al (1960) Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 11:7-33